FCRL5 Molekülinformation
Molecule Name
Fc receptor-like protein 5
Molekülalias
BXMAS1, CD307, CD307e, FCRH5, IRTA2, PRO820
Drug Development Progress
Anzahl der klinischen Arzneimittel3
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Target-Alias
Fc Receptor-Like 5，CD307e Antigen，PRO820，CD307e，Fc Receptor Like 5，FcR-like protein 5，BXMAS1，Fc receptor homolog 5，FcRH5，Immune receptor translocation-associated protein 2，CD_antigen: CD307e，IRTA2，Immunoglobulin Superfamily Receptor Translocation Associated 2 (IRTA2)
Molekülhintergrund
Fc Receptor-Like 5 (FCRL5), also known as FcRH3 (FcRH5 in human), IRTA2, and CD307e, is a 90 ‑ 95 kDa member of the FCRL family of proteins whose amino acid (aa) sequence is reminiscent of that for classical Fc receptors. FCLR molecules are type 1 transmembrane proteins that contain from three to nine immunoglobulin-like domains. They are differentially expressed within the B cell lineage, and can either promote or inhibit B cell proliferation and activation
FCRL5 Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| anti-BCMA/FcRL5 CAR T cell therapy (Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu) | Multiple Myeloma | Details | |
| Anti-FcRL5 CAR-T Cell Therapy(Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu) | Multiple Myeloma | Details | |
| Cevostamab | RG-6160; BFCR-4350A; RO-7187797 | Phase 2 Clinical | Genentech Inc | Lupus Erythematosus, Systemic; Multiple Myeloma | Details |